Premium
Preselection of donors to improve the quality of cryoprecipitate
Author(s) -
Tomasulo Peter A.,
Richards William,
Bailey Marilyn,
Gajewski Mieczyslaw,
Aster Richard H.,
Lazerson Jack
Publication year - 1980
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830080209
Subject(s) - cryoprecipitate , potency , fresh frozen plasma , von willebrand factor , medicine , in vivo , chemistry , in vitro , pharmacology , biochemistry , platelet , microbiology and biotechnology , biology
In theory, the potency of cryoprecipitated antihemophilic factor (cryo) can be increased by utilizing plasma only from donors with high levels of factor VIII procoagulant activity (fVIII c ). Previous reports have suggested that plasma of group O individuals has, on the average, less fVIII c than plasma from individuals of blood groups A, B, and AB. We have investigated the feasibility of increasing the potency of cryo by preselecting plasma for cryo production on the basis of the blood group of the donor. FVIII c levels of fresh plasma, fresh frozen plasma (FFP), and cryo (prepared both by air‐thaw and water‐thaw methods) were assayed. The plasma, FFP, and cryo from group O donors contained only 75% of the fVIII c present in plasma from group A, group B, and group AB donors. Following infusion to patients with hemophilia, in vivo recovery and survival of fVIII c activity from groups A, B, and AB cryo reflected the higher in vitro levels. The mean potency of bags of cryo can be increased, and the cost of hemophilia treatment with cryo can be reduced by excluding group O plasma from the production of cryoprecipitate.